Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
Galectin's stock halves after phase 3 MASH trial misses goal
Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Gabrielle Masson
Dec 20, 2024 2:40pm
Viking liver disease drug reduces fibrosis in final ph. 2 data
Nov 20, 2024 3:20pm
GSK’s itch prospect hits mark in phase 3 liver disease trial
Nov 19, 2024 8:24am
AZ licenses discarded rare disease drug to Monopar Therapeutics
Oct 24, 2024 2:54pm
Rectify drug repairs bile composition in mice with liver disease
Oct 22, 2024 7:00am
Gilead pays J&J $320M to exit licensing deal for seladelpar
Aug 9, 2024 10:30am
